Capital World Investors’s Ascendis Pharma A/S ASND Stock Holding History

Capital World Investors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242M	Buy	906,081 +5,564	+0.6%	+$1.3M	0.03%	305
2026 Q1	$206M	Buy	+900,517	New	+$202M	0.03%	304

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital World Investors's ASND Position: Q2 2026 in Review

Capital World Investors increased its Ascendis Pharma A/S (ASND) stake by 0.62% in Q2 2026, buying an estimated $1.3M and bringing the position to 906,081 shares worth $242M. The position accounts for 0.03% of the portfolio, ranked #305.

Capital World Investors first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Capital World Investors held 906,081 shares of Ascendis Pharma A/S worth $242M as of Q2 2026.
Capital World Investors bought 5,564 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.3M.
Ascendis Pharma A/S made up 0.03% of Capital World Investors's portfolio in Q2 2026, its #305 holding.
Capital World Investors first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.